Copyright
©The Author(s) 2015.
World J Gastroenterol. Apr 21, 2015; 21(15): 4696-4706
Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4696
Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4696
Table 1 Baseline demographic characteristics, classified by treatment
Baseline characteristics | Triple therapy (n = 88) | Dual therapy (n = 122) | P value |
Age, yr | 63 (53-68) | 60 (52-65) | 0.101 |
Male | 37 (42.1) | 52 (42.6) | 0.933 |
Body weight, kg | 56 (49-67) | 58 (50-66) | 0.782 |
Body mass index, kg/m2 | 22.7 (20.7-25.1) | 22.8 (20.6-24.9) | 0.859 |
Serum AFP level, ng/mL | 4.5 (2.8-9.0) | 4.0 (2.8-8.9) | 0.677 |
Serum AFP level < 5 ng/mL | 50 (56.8) | 70 (57.4) | 0.967 |
Serum AFP level 5-9.9 ng/mL | 18 (20.5) | 26 (21.3) | |
Serum AFP level ≥ 10 ng/mL | 20 (20.7) | 26 (21.3) | |
HCV RNA level, log10 IU/mL | 6.5 (6.1-6.9) | 6.3 (5.8-6.6) | 0.010 |
HCV genotype 1a | 1 (1.1) | 3 (2.5) | 0.476 |
HCV genotype 1b | 87 (98.9) | 119 (97.5) | |
Serum albumin, g/L | 41 (38-43) | 41 (39-43) | 0.376 |
Alanine aminotransferase, U/L | 46 (25-73) | 51 (33-81) | 0.176 |
Alanine aminotransferase ≥ 40 IU/L | 49 (55.7) | 78 (63.9) | 0.228 |
γ-glutamyl-transpeptidase, U/L | 39 (23-76) | 37 (21-63) | 0.199 |
Estimated glomerular filtration rate, mL/min per 1.73 m2 | 80 (68-94) | 81 (71-94) | 0.464 |
Total cholesterol, mg/dL | 175 (153-192) | 164 (146-192) | 0.216 |
Triglycerides, mg/dL | 94 (68-124) | 79 (57-121) | 0.070 |
Aspartate aminotransferase to platelet ratio index | 0.86 (0.51-1.85) | 0.76 (0.50-1.40) | 0.306 |
White blood cell count, × 106/L | 4780 (4038-5890) | 4600 (3890-5645) | 0.447 |
Hemoglobin level, g/L | 137 (129-144) | 135 (126-145) | 0.319 |
Platelet count, × 109/L | 156 (122-195) | 178 (136-209) | 0.040 |
Diabetes | 10 (11.3) | 7 (5.7) | 0.144 |
Stage of fibrosis | |||
F0-2 | 52 (81.2) | 76 (90.5) | 0.105 |
F3-4 | 12 (18.8) | 8 (9.5) | |
Not determined, n | 24 | 38 | |
Previous treatment response | |||
Naïve | 25 (28.4) | ||
Prior relapse | 34 (38.6) | ||
Prior NVR | 27 (30.7) | ||
Prior unknown response | 2 (2.3) | ||
IL28B SNP (rs8099917) | |||
TT | 49 (55.7) | 73 (70.2) | 0.113 |
TG/GG | 39 (44.3) | 31 (29.8) | |
Not determined, n | 0 | 18 |
Table 2 Sustained virological response rates n (%)
Group | Triple therapy | Dual therapy | P value | ||
n | SVR | n | SVR | ||
All patients | 88 | 75 (85.2) | 122 | 52 (42.6) | < 0.001 |
Previous treatment response | |||||
Naïve/prior relapse | 59 | 56 (94.9) | |||
Prior NVR | 27 | 17 (63.0) | |||
Prior unknown response | 2 | 2 (100) | |||
IL28B SNP (rs8099917) | |||||
TT | 49 | 48 (98.0) | 73 | 45 (61.6) | < 0.001 |
TG/GG | 39 | 27 (69.2) | 31 | 1 (3.2) | < 0.001 |
Not determined, n | 0 | - | 18 | 6 (33.3) | - |
Stage of fibrosis | |||||
F0-2 | 52 | 48 (92.3) | 76 | 43 (56.6) | < 0.001 |
F3-4 | 12 | 9 (75.0) | 8 | 4 (50.0) | 0.279 |
Not determined, n | 24 | 18 (75.0) | 38 | 5 (13.2) | |
Baseline HCV RNA level | |||||
≥ 6 log10 IU/mL | 69 | 58 (84.1) | 86 | 39 (45.3) | < 0.001 |
< 6 log10 IU/mL | 19 | 17 (89.5) | 36 | 23 (63.8) | 0.032 |
Baseline platelet count | |||||
≥ 100 × 109/L | 80 | 71 (88.8) | 117 | 62 (53.0) | < 0.001 |
< 100 × 109/L | 8 | 4 (50.0) | 5 | 0 - | 0.043 |
Baseline serum AFP level | |||||
< 10 ng/mL | 68 | 63 (92.6) | 96 | 49 (51.0) | < 0.001 |
≥ 10 ng/mL | 20 | 12 (60.0) | 26 | 3 (11.5) | < 0.001 |
Table 3 Serum alpha-fetoprotein level change at each testing point
Group | Triple therapySerum AFP level (ng/mL) | Dual therapySerum AFP level (ng/mL) | ||||||||
n | At baseline | At end of treatment | At 24 wk after the end of treatment | P value1 | n | At baseline | At end of treatment | At 24 wk after the end of treatment | P value1 | |
All patients | 88 | 8.8 ± 1.4 | 5.1 ± 0.4 | 4.4 ± 0.4 | < 0.001 | 122 | 7.8 ± 0.9 | 6.2 ± 1.3 | 7.0 ± 1.5 | 0.316 |
Treatment outcome | ||||||||||
SVR | 75 | 7.8 ± 1.5 | 4.5 ± 0.4 | 3.5 ± 0.2 | 0.004 | 52 | 4.7 ± 0.6 | 3.1 ± 0.2 | 2.8 ± 0.2 | < 0.001 |
Non-SVR | 13 | 14.3 ± 2.3 | 8.3 ± 1.1 | 9.5 ± 1.2 | 0.007 | 70 | 10.2 ± 1.5 | 8.7 ± 2.2 | 10.1 ± 2.5 | 0.953 |
Baseline AFP level | ||||||||||
≥ 10 ng/mL | 20 | 24.8 ± 4.4 | 10.5 ± 1.0 | 8.9 ± 0.8 | 0.003 | 26 | 21.8 ± 3.0 | 17.1 ± 5.3 | 20.2 ± 6.4 | 0.701 |
< 10 ng/mL | 68 | 4.1 ± 0.2 | 3.4 ± 0.2 | 3.1 ± 0.2 | < 0.001 | 96 | 4.1 ± 0.2 | 3.2 ± 0.2 | 3.4 ± 0.2 | < 0.001 |
Previous treatment response | ||||||||||
Naïve/prior relapse | 59 | 8.8 ± 1.9 | 4.8 ± 0.5 | 3.8 ± 0.3 | 0.007 | |||||
Prior NVR | 27 | 9.1 ± 1.5 | 5.5 ± 0.8 | 5.8 ± 0.9 | < 0.001 | |||||
IL28B SNP (rs8099917) | ||||||||||
TT | 49 | 6.2 ± 1.0 | 3.9 ± 0.4 | 3.6 ± 0.3 | < 0.001 | 73 | 6.0 ± 0.7 | 3.7 ± 0.3 | 3.9 ± 0.3 | < 0.001 |
TG/GG | 39 | 12.0 ± 2.8 | 6.5 ± 0.8 | 5.5 ± 0.6 | < 0.001 | 31 | 10.2 ± 1.6 | 8.8 ± 2.9 | 9.3 ± 2.2 | 0.520 |
Stage of fibrosis | ||||||||||
F0-2 | 52 | 6.5 ± 1.4 | 4.2 ± 0.5 | 3.3 ± 0.3 | 0.014 | 76 | 6.0 ± 0.7 | 3.7 ± 0.3 | 4.3 ± 0.5 | < 0.001 |
F3-4 | 12 | 12.2 ± 3.0 | 6.5 ± 0.8 | 6.8 ± 1.1 | 0.023 | 8 | 13.6 ± 3.2 | 9.2 ± 3.2 | 9.9 ± 3.8 | 0.284 |
Table 4 Alanine aminotransferase level change at each testing point
Group | Triple therapyALT level (U/L) | Dual therapyALT level (U/L) | ||||||||
n | At baseline | At end of treatment | At 24 wk after the end of treatment | P value1 | n | At baseline | At end of treatment | At 24 wk after the end of treatment | P value1 | |
All patients | 88 | 56.6 ± 4.1 | 25.9 ± 2.4 | 22.7 ± 1.8 | < 0.001 | 122 | 64.1 ± 4.7 | 29.4 ± 4.0 | 35.3 ± 3.0 | < 0.001 |
Treatment outcome | ||||||||||
SVR | 75 | 54.3 ± 4.3 | 25.4 ± 2.7 | 17.8 ± 1.1 | < 0.001 | 52 | 74.0 ± 7.3 | 18.8 ± 1.6 | 14.9 ± 0.8 | < 0.001 |
Non-SVR | 13 | 69.8 ± 12.2 | 28.8 ± 3.8 | 50.6 ± 6.0 | 0.147 | 70 | 56.8 ± 4.9 | 37.4 ± 6.7 | 50.4 ± 4.3 | 0.169 |
Baseline ALT level | ||||||||||
≥ 40 U/L | 49 | 81.4 ± 5.1 | 32.9 ± 3.5 | 28.5 ± 2.8 | < 0.001 | 78 | 84.3 ± 5.4 | 36.6 ± 5.9 | 40.0 ± 4.2 | < 0.001 |
< 40 U/L | 39 | 25.4 ± 1.2 | 17.1 ± 2.6 | 15.4 ± 1.3 | < 0.001 | 44 | 28.3 ± 1.1 | 16.0 ± 1.7 | 26.8 ± 3.0 | 0.637 |
Previous treatment response | ||||||||||
Naïve/Prior relapse | 59 | 56.5 ± 5.2 | 25.5 ± 2.7 | 19.4 ± 1.5 | < 0.001 | |||||
Prior NVR | 27 | 56.7 ± 7.5 | 21.0 ± 2.5 | 28.6 ± 4.5 | < 0.001 | |||||
IL28B SNP (rs8099917) | ||||||||||
TT | 49 | 56.9 ± 5.4 | 26.6 ± 3.8 | 17.4 ± 1.3 | < 0.001 | 73 | 63.6 ± 5.4 | 18.9 ± 1.4 | 25.9 ± 2.4 | < 0.001 |
TG/GG | 39 | 56.2 ± 6.5 | 24.9 ± 2.6 | 29.2 ± 3.5 | < 0.001 | 31 | 65.9 ± 9.4 | 38.8 ± 6.2 | 50.9 ± 5.2 | 0.073 |
Stage of fibrosis | ||||||||||
F0-2 | 52 | 51.6 ± 5.2 | 23.1 ± 3.2 | 17.6 ± 1.5 | < 0.001 | 76 | 63.4 ± 5.4 | 21.1 ± 1.7 | 25.4 ± 2.4 | < 0.001 |
F3-4 | 12 | 68.8 ± 11.6 | 32.3 ± 5.6 | 27.5 ± 5.4 | 0.008 | 8 | 93.0 ± 25.8 | 34.8 ± 7.6 | 46.5 ± 11.8 | 0.172 |
- Citation: Takayama K, Furusyo N, Ogawa E, Ikezaki H, Shimizu M, Murata M, Hayashi J. Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. World J Gastroenterol 2015; 21(15): 4696-4706
- URL: https://www.wjgnet.com/1007-9327/full/v21/i15/4696.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i15.4696